RIVUR - Randomized Intervention for Children with Vesicoureteral Reflux

There is no guarantee that you will receive any direct benefit from participating in this study. However, the information which is obtained from this study will be useful scientifically and may be helpful to others. We hope that this study may benefit society by showing which approach is better for treating children with VUR.

The standard testing in this study will provide information about your child’s disease that may be beneficial to your child’s well-being. For example, the DMSA scan could allow early discovery of kidney scars. This would alert the doctors to closely monitor your child so that the risk of new scars might be decreased. The blood and urine tests may also provide early information about kidney damage.

Benefits of the study medication include:

Placebo group: Children in the placebo group may be less likely to become infected with resistant organisms that would require treatment with intravenous (IV) antibiotics. Children in this group will not develop the potential allergies or adverse events caused by antibiotic prophylaxis.
Prophylactic Antibiotic group: If daily antibiotic prophylaxis is protective against recurrence of UTI and renal scarring, then children in the antibiotic group may have fewer UTIs and less risk of renal scarring.

To help cover any expenses such as transportation or time off from work during the clinic visits, you will receive compensation. For more information about benefits of participation and compensation, please contact the study coordinator at the RIVUR clinic nearest you. (See Institutions page.)